1. Role of N-Arachidonoyl-Serotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation
   Eric Murillo-Rodríguez et al, 2017, Front. Mol. Neurosci. CrossRef
2. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice
   F. Guida et al, 2018, Brain, Behavior, and Immunity CrossRef
3. Activation of dorsal horn cannabinoid CB2 receptor suppresses the expression of P2Y12 and P2Y13 receptors in neuropathic pain rats
   Juan Niu et al, 2017, J Neuroinflammation CrossRef
4. Novel analgesic effects of melanin-concentrating hormone on persistent neuropathic and inflammatory pain in mice
   Jae-Hwan Jang et al, 2018, Sci Rep CrossRef
5. The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents
   Guy Griebel et al, 2018, Sci Rep CrossRef
6. The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation
   Dinesh Thapa et al, 2018, Cannabis and Cannabinoid Research CrossRef
7. Psychological Pain, Depression, and Suicide: Recent Evidences and Future Directions
   Ismael Conejero et al, 2018, Curr Psychiatry Rep CrossRef
8. Acute oral Cannabidiolic Acid Methyl Ester reduces depression-like behavior in two genetic animal models of depression
   D. Hen-Shoval et al, 2018, Behavioural Brain Research CrossRef
9. null
   , 2018 CrossRef
10. The role of cannabinoids in pain control: the good, the bad, and the ugly
    Joseph V. Pergolizzi Jr. et al, 2018, Minerva Anestesiol CrossRef
11. Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
    Marina Peball et al, 2019, J Neural Transm CrossRef
12. Antinociceptive and antidepressive efficacies of the combined ineffective doses of S-ketamine and URB597
    Mohaddeseh Ebrahimi-Ghiri et al, 2019, Naunyn-Schmiedeberg's Arch Pharmacol CrossRef
13. Endocannabinoid modulation of inflammatory hyperalgesia in the IFN-α mouse model of depression
    Marie Fitzgibbon et al, 2019, Brain, Behavior, and Immunity CrossRef
14. Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits
    Sophie E. Legge et al, 2019, JAMA Psychiatry CrossRef
15. Serum Endocannabinoid and Mood Changes after Exercise in Major Depressive Disorder
    JACOB D. MEYER et al, 2019, Medicine & Science in Sports & Exercise CrossRef
16. Disease‐associated polymorphisms within the conserved ECR1 enhancer differentially regulate the tissue‐specific activity of the cannabinoid‐1 receptor gene promoter; implications for cannabinoid pharmacogenetics
    Elizabeth A. Hay et al, 2019, Human Mutation CrossRef
17. null
    Antonella Ciaramella, 2019 CrossRef
18. Relationship Between Cannabis Use and Erectile Dysfunction: A Systematic Review and Meta-Analysis
    Damiano Pizzol et al, 2019, Am J Mens Health CrossRef
19. Altered SWD stopping mechanism in WAG/Rij rats subchronically treated with the cannabinoid agonist R(+)WIN55,212-2
    Martin F.J. Perescis et al, 2020, Epilepsy & Behavior CrossRef
20. A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents
    Rati Kailash Prasad Tripathi, 2019, European Journal of Medicinal Chemistry CrossRef
21. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation
    Dinesh Thapa et al, 2020, Molecules CrossRef
22. Reciprocal association between depression and peptic ulcers: Two longitudinal follow-up studies using a national sample cohort
    So Young Kim et al, 2020, Sci Rep CrossRef
23. Protective effects of N-oleoylglycine in a mouse model of mild traumatic brain injury
    Fabiana Piscitelli et al, 2020, ACS Chem. Neurosci. CrossRef
24. Molecular docking utilising the OliveNetTM Library reveals novel phenolic compounds which may potentially target key proteins associated with major depressive disorder
    Eleni Pitsillou et al, 2020, Computational Biology and Chemistry CrossRef
25. Chromatin modification by olive phenolics: In silico molecular docking studies utilising the phenolic groups categorised in the OliveNet™ database against lysine specific demethylase enzymes
    Eleni Pitsillou et al, 2020, Journal of Molecular Graphics and Modelling CrossRef
26. N6-methyladenosine modification of FAAH mRNA in circSTAG1-regulated astrocyte dysfunction and depressive-like behaviors
    Rongrong Huang et al, 2020, Biological Psychiatry CrossRef
27. Cannabinoids as anticancer therapeutic agents.
    Olga Kovalchuk et al, 2020, Cell Cycle CrossRef
28. Inner Engineering Practices and Advanced 4-day Isha Yoga Retreat Are Associated with Cannabimimetic Effects with Increased Endocannabinoids and Short-Term and Sustained Improvement in Mental Health: A Prospective Observational Study of Meditators
    Senthilkumar Sadhasivam et al, 2020, Evidence-Based Complementary and Alternative Medicine CrossRef
29. Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?
    Tomasz Charytoniuk et al, 2020, IJMS CrossRef
30. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities
    Dixon H. Xu et al, 2020, CPB CrossRef
31. Cannabidiol primer for healthcare professionals
    Jennifer Clay Cather et al, 2020, Baylor University Medical Center Proceedings CrossRef
32. Maternal separation plus social isolation during adolescence reprogram brain dopamine and endocannabinoid systems and facilitate alcohol intake in rats
    Octavio Amancio-Belmont et al, 2020, Brain Research Bulletin CrossRef
33. The Circadian Hormone Melatonin Inhibits Morphine-Induced Tolerance and Inflammation via the Activation of Antioxidative Enzymes
    Ing-Jung Chen et al, 2020, Antioxidants CrossRef
34. Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.
    Marina Peball et al, 2020, Ann Neurol CrossRef
35. Common Pathways for Pain and Depression-Implications for Practice
    Maria-Mirabela Mihailescu-Marin et al, 2020 CrossRef
36. null
    Garth E. Terry et al, 2021 CrossRef
37. The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders
    Qing Xin et al, 2020, Acta Pharmacol Sin CrossRef
38. Mechanisms of repetitive transcranial magnetic stimulation for anti-depression: Evidence from preclinical studies
    Di Luan et al, 2020, WJP CrossRef
39. Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system
    Danko Jeremic et al, 2021, Pharmacology & Therapeutics CrossRef
40. Increased Anandamide and Decreased Pain and Depression after Exercise in Fibromyalgia
    NICLAS STENSSON et al, 2020 CrossRef
41. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists
    Eun Yong Chung et al, 2021, Arch. Pharm. Res. CrossRef
42. An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients
    Simon Erridge et al, 2021, Neuropsychopharmacol Rep CrossRef
43. Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression
    Ferenc Zádor et al, 2021, IJMS CrossRef
44. null
    Dafin F. Muresanu et al, 2021 CrossRef
45. The Endocannabinoidome in Neuropsychiatry: Opportunities and Potential Risks
    Gerwyn Morris et al, 2021, Pharmacological Research CrossRef
46. An investigation into the anxiety-relieving and mood-enhancing effects of Echinacea angustifolia (EP107™): a randomised, double-blind, placebo-controlled study
    Adrian L Lopresti et al, 2021, Journal of Affective Disorders CrossRef
47. BDNF Impact on Biological Markers of Depression—Role of Physical Exercise and Training
    Eugenia Murawska-Ciałowicz et al, 2021, IJERPH CrossRef
48. The GPR18 Agonist PSB-KD-107 Exerts Endothelium-Dependent Vasorelaxant Effects
    Magdalena Kotańska et al, 2021, Pharmaceuticals CrossRef
49. Virtual screening using Docking and Molecular Dynamics of cannabinoid analogues against CB1 and CB2 receptors
    Antistio Avíz-Amador et al, 2021, Computational Biology and Chemistry CrossRef
50. null
    Yuri Chaves Martins, 2021 CrossRef
51. Mental health and quality of life in a population of recreative cannabis users in Brazil
    Paulo Rogério Morais et al, 2021, Journal of Psychiatric Research CrossRef
52. The Biology of BDSM: A Systematic Review
    Elise Wuyts et al, 2022, The Journal of Sexual Medicine CrossRef
53. UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes
    Devaki Nimalan et al, 2022, J Cannabis Res CrossRef
54. Maternal separation: Does it hold the potential to model consequences of postpartum depression?
    Annakarina Mundorf et al, 2022, Developmental Psychobiology CrossRef
55. Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition
    Alessandro Papa et al, 2022, Cells CrossRef
56. null
    , 2022 CrossRef
57. Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults
    Jodi M. Gilman et al, 2022, JAMA Netw Open CrossRef
58. Abstinence from Chronic Methylphenidate Exposure Modifies Cannabinoid Receptor 1 Levels in the Brain in a Dose-dependent Manner
    Carly Connor et al, 2022, CPD CrossRef
59. Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice
    Amaya Austrich-Olivares et al, 2022, Pharmaceuticals CrossRef
60. ΒN-Alkanoyl-5-Hydroxytryptamines (Cn-5HTs) in Coffee: A Review
    A. L. M. Brand et al, 2022, Food Reviews International CrossRef
61. Development and molecular modeling studies of new thiadiazole piperazine urea derivatives as potential fatty acid amide hydrolase inhibitors
    Tugce Gur Maz et al, 2022, Archiv der Pharmazie CrossRef
62. Higher Risk of Anxiety and Depression in Women with Adenomyosis as Compared with Those with Uterine Leiomyoma
    Ni Li et al, 2022, JCM CrossRef
63. Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post‐hoc Analysis of NMS‐Nab Study
    Marina Peball et al, 2022, Movement Disord Clin Pract CrossRef
64. Characterizing chronic non-suicidal self-injury and other forms of repetitive and escalating suicide behaviour as endocannabinoid-mediated pain and reward disorders
    Hye Ji J. Kim et al, 2022, Personalized Medicine in Psychiatry CrossRef
65. Potential Mechanisms and Clinical Effectiveness of Acupuncture in Depression
    Na-Na Yang et al, 2022, CN CrossRef
66. Study protocol for a phase II, double-blind, randomised controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain
    Chelsea K Pike et al, 2022, BMJ Open CrossRef
67. Muscone with Attenuation of Neuroinflammation and Oxidative Stress Exerts Antidepressant-Like Effect in Mouse Model of Chronic Restraint Stress
    Hua Liu et al, 2022, Oxidative Medicine and Cellular Longevity CrossRef
68. Schisandra chinensis Lignans Exert Antidepressant Effects by Promoting BV2 Microglia Polarization toward the M2 Phenotype through the Activation of the Cannabinoid Receptor Type-2–Signal Transducer and Activator of Transcription 6 Pathway
    Jinyu Wang et al, 2022, J. Agric. Food Chem. CrossRef
69. null
    Dafin F. Muresanu et al, 2022 CrossRef
70. Risk of depressive disorders associated with medical cannabis authorization: a propensity score matched cohort study
    Jerry Liwono Yana et al, 2023, Psychiatry Research CrossRef
71. M3 Receptor Pathway Stimulates Rapid Transcription of the CB1 Receptor Activation through Calcium Signalling and the CNR1 Gene Promoter
    Pietro Marini et al, 2023, IJMS CrossRef
72. Endocannabinoid System: Chemical Characteristics and Biological Activity
    Bismarck Rezende et al, 2023, Pharmaceuticals CrossRef
73. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
    Ahmed Hasbi et al, 2023, Brain Sciences CrossRef
74. Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry
    James Tait et al, 2023, Expert Review of Neurotherapeutics CrossRef
75. Substance abuse and male sexual dysfunction: what lies beneath?
    Taymour Mostafa et al, 2023 CrossRef